Topiroxostat
Chemical compound
- None
- Approved in Japan
- 4-[5-(4-Pyridinyl)-1H-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile
- 577778-58-6
- 5288320
- 4450517
- 0J877412JV
- DTXSID80206462
- Interactive image
- C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
InChI
- InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
- Key:UBVZQGOVTLIHLH-UHFFFAOYSA-N
Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.[1] It was approved for use in Japan in June 2013.[1]
Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.[2]
References
- ^ a b "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. (December 2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. 18 (6): 876–84. doi:10.1007/s10157-014-0935-8. PMC 4271138. PMID 24448692.
- v
- t
- e
Drugs used for gout (M04)
| primary | |
|---|---|
| secondary |
| purine analogues | |
|---|---|
| other |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
